Results 81 to 90 of about 20,698 (251)

Semaglutide for the treatment of overweight and obesity: A review

, 2023
Obesity is a chronic, relapsing disease associated with multiple complications and a substantial morbidity, mortality and health care burden. Pharmacological treatments for obesity provide a valuable adjunct to lifestyle intervention, which often ...
NC Bergmann (17025585), MJ Davies (7347098), FK Knop (7783331), I Lingvay (7711226)   +3 more
core   +2 more sources

Subcutaneous injection of semaglutide causes increased muscle uptake of 18F-FDG and reduces the imaging quality of PET/CT: a case report

EJNMMI Research
Background Semaglutide, a glucagon-like peptide-1 receptor agonist widely used in diabetes management, has not been previously reported to interfere with PET/CT imaging. This case highlights a novel observation regarding same-day subcutaneous semaglutide
Dong-chun Hong, Liyuan Le, Weipeng Chen, Wen Long, Wei Fan   +4 more
doaj   +1 more source

Precision Medicine in Neurodegeneration with Brain Iron Accumulation (NBIA) Disorders: An Update on Emerging Treatments

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Neurodegeneration with Brain Iron Accumulation (NBIA) is a heterogeneous group of heritable, mostly recessive, progressive neurodegenerative diseases characterized by iron deposition in the basal ganglia and brainstem. There are no solid global epidemiological data on prevalence and incidence of NBIA subtypes, but registry data and ...
Susanne A. Schneider, Divyani Garg, Vassilena Iankova, Thomas Klopstock   +3 more
wiley   +1 more source

Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice

Frontiers in Pharmacology
BackgroundThe purpose of this study was to explore how semaglutide, a GLP-1RA, regulates serum metabolism and gut microbiota to improve obesity in mice and whether fecal microbiota transplantation (FMT) can transmit the beneficial effects of semaglutide ...
Luyan Sun, Bingqing Shang, Suyuan Lv, Guolong Liu, Qiu Wu, Yue Geng   +5 more
doaj   +1 more source

The role of semaglutide in obesity management: mechanism of action and future directions

Literature review, understanding and overview of current trend of semaglutide usage in treatment specifically obesity and weight management, its risks, safety factors and ways forward for the future health wellbeing.BSc/BABiochemical ...
Sekulović, Aleksandra
core  

Therapeutic Impact of GLP‐1 Receptor Agonists on Parkinson's Disease: A Scoping Review

Neurology and Clinical Neuroscience, EarlyView.
ABSTRACT No disease‐modifying treatment exists for Parkinson's disease (PD). Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have gained attention as promising candidates for neuroprotection, given documented expression of GLP‐1 receptors within the central nervous system and the contribution of brain insulin resistance to dopaminergic ...
João Pedro Henriques, João Pedro Stringhetta Rahal, Rafael da Cunha Gomes Ribeiro, Enzo Bogucheski Ribeiro Machado, Carlos Antonio Negrato   +4 more
wiley   +1 more source

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi, Alvin Chandra, Ambarish Pandey, Marco Metra   +3 more
wiley   +1 more source

Incretin‐Based Therapies: A Testable Hypothesis Linking Incretin Signaling, Mitochondrial Redox, and OXPHOS Efficiency

Obesity, EarlyView.
ABSTRACT Objective Incretin‐based obesity therapies (IBTs), especially GLP‐1 receptor agonists (GLP‐1 RAs), effectively treat obesity and improve comorbidities. However, their impact on energy metabolism is unclear. A recent case of acute generalized muscle weakness in a patient with mitochondrial myopathy after tirzepatide exposure raises concerns ...
Bryn Falahee, Caroline M. Apovian, Nawfal Istfan   +2 more
wiley   +1 more source

Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy [PDF]

Importance Semaglutide, a glucagonlike peptide-1 receptor agonist (GLP-1RA), has recently been implicated in cases of nonarteritic anterior ischemic optic neuropathy (NAION), raising safety concerns in the treatment of type 2 diabetes (T2D).
Adibuzzaman, Mohammad, Weiskopf, Nicole G, Agrawal, Rupesh, Lee, Lok Hin, Boyce, Danielle, Baxter, Sally, Boland, Michael V., Matheny, Michael, Chen, Aiyin, Takkouche, Sahar, Stocking, Jacqueline C., Bu, Fan, Wilcox, Adam, Nishimura, Akihiko, Hripcsak, George, Nagy, Paul, Westlund, Erik, Hribar, Michelle, McCoy, David B., Flowers, Alexis, Areaux, Raymond G., Suchard, Marc A, Ehrlich, Joshua R., Viernes, Benjamin, Lee, David A, Suchard, Marc A., Lee, Cecilia, Dorr, David, Ryan, Patrick B, Cai, Cindy X., Lai, Albert, Mawn, Louise, Cai, Cindy X, Wang, Sophia, Brown, Eric N., Areaux, Raymond G, Falconer, Thomas, DuVall, Scott L, Stocking, Jacqueline C, Armbrust, Karen R., Sena, Anthony G., Goetz, Kerry, Rojas-Carabali, William, Mathioudakis, Nestoras, Swaminathan, Swarup S., Swaminathan, Swarup S, Chen, John, Toy, Brian, Alshammari, Thamir, O\u27Brien, William, O'Brien, William, Xie, Yangyiran, Brown, Eric N, Swerdel, Joel, Ryan, Patrick B., Armbrust, Karen R, Barkmeier, Andrew, Leng, Theodore, Xu, Benjamin, Schuemie, Martijn, Fan, Ruochong, Weiskopf, Nicole G., Ehrlich, Joshua R, McCoy, David B, Martin, Benjamin, Zhang, Linying, Humes, Izabelle, Morgan-Cooper, Hannah, Brash, James, Lee, David A., Boland, Michael V, Desai, Priya, Sena, Anthony G, Duvall, Scott L.   +73 more
core   +1 more source

From cytokine storm to renal scarring in diabetic kidney disease: Biomarkers, risk stratification, and precision therapeutics

Precision Medical Sciences, EarlyView.
Hyperglycemia‐driven cytokine activation initiates a sustained inflammatory cascade in diabetic kidney disease, promoting cellular injury and fibrogenic signaling. Integrating cytokine‐based biomarkers with risk stratification enables precision therapeutics that target inflammation and fibrosis, ultimately aiming to halt progression from early renal ...
Emmanuel Ifeanyi Obeagu
wiley   +1 more source